<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.7.3" -->
<rss version="2.0">
	<channel>
		<title>FDA Calendar  Extreme Trades: 30 Stocks Under $5</title>
		<description>Comments for FDA Calendar  Extreme Trades: 30 Stocks Under $5 at http://www.biomedreports.com , comment 1 to 5 out of 5 comments</description>
		<link>http://www.biomedreports.com</link>
		<lastBuildDate>Wed, 08 Feb 2012 03:02:16 +0100</lastBuildDate>
        <generator>FeedCreator 1.7.3</generator>
		<item>
			<title>...</title>
			<link>http://www.biomedreports.com/200908013969/fda-calendar-extreme-trades-30-stocks-under-5.html#comment-711</link>
			<description>good stock - rabee khayat</description>
			<pubDate>Thu, 27 Aug 2009 03:02:30 +0100</pubDate>
		</item>
		<item>
			<title>...</title>
			<link>http://www.biomedreports.com/200908013969/fda-calendar-extreme-trades-30-stocks-under-5.html#comment-603</link>
			<description>How about PPHM? This is also under $5.00. Don't you think this stock should be amongst the 30 stocks under $5. - Eric Alexander</description>
			<pubDate>Sat, 08 Aug 2009 03:10:22 +0100</pubDate>
		</item>
		<item>
			<title>...</title>
			<link>http://www.biomedreports.com/200908013969/fda-calendar-extreme-trades-30-stocks-under-5.html#comment-596</link>
			<description>How about BVTI?  I like BVTI better than lots of others given the approval in eupore for its cancer drug. I also wonder why there has not been FDA filing for NDA yet. I am sure the approval would be worth billions for BVTI given the fact that it extends life expectancy by almost 300% in cancer patients from current survival rate. - sumesh</description>
			<pubDate>Mon, 03 Aug 2009 23:47:57 +0100</pubDate>
		</item>
		<item>
			<title>...</title>
			<link>http://www.biomedreports.com/200908013969/fda-calendar-extreme-trades-30-stocks-under-5.html#comment-593</link>
			<description>Thanks for the updates and including the share price - helps me to target companies for further due diligence.

Any reason why GETA wasn't included?  I know they are broke.  But shareholders had enough faith in the company to approve a reverse split.  Their current phase 3 trial (I think expected to report findings this quarter) was based on outcomes of the previous phase 2 - a subset of responsive patients.  This seems to be working for other biotechs (DNDN, HGSI to name a couple).

Also PSDV?  I looked into them and they have already been thru the FDA process successfully with 2 approved eye meds.  A little difficult to buy into - was on Scottrades watch list - but their newest drug delivery system for DME looked very promising to me.

TIA - kathy johnson</description>
			<pubDate>Sun, 02 Aug 2009 22:44:21 +0100</pubDate>
		</item>
		<item>
			<title>...</title>
			<link>http://www.biomedreports.com/200908013969/fda-calendar-extreme-trades-30-stocks-under-5.html#comment-585</link>
			<description>Hello
There someone has news concerning SUNESIS PHARMACEUTICALS   snss
thanks - motmans</description>
			<pubDate>Sun, 02 Aug 2009 08:40:18 +0100</pubDate>
		</item>
	</channel>
</rss>

